Patents by Inventor Roelf Datema
Roelf Datema has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10456379Abstract: The present invention relates to novel therapeutic agents suitable for use in the treatment of mammalian disease and in particular to novel therapeutic agents suitable for use in the treatment of microbial infection in mammals. The present invention further relates to the use of pharmaceutical compositions comprising said agents in the treatment of medical conditions in mammals, in particular in the treatment of microbial infection. The agents and pharmaceutical compositions of the invention are of particular relevance in the treatment of diseases associated with antibiotic-resistant microbes.Type: GrantFiled: December 3, 2015Date of Patent: October 29, 2019Assignee: Procomcure Biotech GmbHInventors: Kamil Önder, Roelf Datema
-
Patent number: 10322110Abstract: The present invention relates to therapeutic agents suitable for use in the treatment of microbial infection in mammals. The present invention further relates to the use of pharmaceutical compositions comprising said agents in the treatment of medical conditions in mammals, in particular in the treatment of microbial infection. The agents and pharmaceutical compositions of the invention are of particular relevance in the treatment of diseases associated with antibiotic-resistant microbes. In one particular embodiment, the pharmaceutical composition can have the structural moiety of formula (I) or a pharmaceutically-acceptable salt of said compound: wherein group A is selected from the formulae Group B is aryl, R1 is an optionally substituted aryl ring, an optionally substituted benzyl ring, CH3, or C2 to 6 alkyl, and R2 is hydrogen, an alkyl group, a halogen, or —(CH2)nN(CH3)2 where n is an integer from 1 to 3.Type: GrantFiled: December 3, 2015Date of Patent: June 18, 2019Assignee: Procomcure Biotech GmbHInventors: Kamil Önder, Roelf Datema, Dale Mitchell, Ivan Kondratov
-
Patent number: 10314820Abstract: The present invention relates to novel compounds of formula (I) suitable e.g. as therapeutic agents for use in the treatment of mammalian disease and in particular to novel therapeutic agents suitable for use in the treatment of microbial infection in mammals. The present invention further relates to the use of pharmaceutical compositions comprising said agents in the treatment of medical conditions in mammals, in particular in the treatment of microbial infection. The agents and pharmaceutical compositions of the invention are of particular relevance in the treatment of diseases associated with antibiotic-resistant microbes. The present invention also relates to processes for making said agents.Type: GrantFiled: December 3, 2015Date of Patent: June 11, 2019Assignee: Procomcure Biotech GmbHInventors: Kamil Önder, Roelf Datema, Dale Mitchell, Ivan Kondratov
-
Publication number: 20170368032Abstract: The present invention relates to novel therapeutic agents suitable for use in the treatment of mammalian disease and in particular to novel therapeutic agents suitable for use in the treatment of microbial infection in mammals. The present invention further relates to the use of pharmaceutical compositions comprising said agents in the treatment of medical conditions in mammals, in particular in the treatment of microbial infection. The agents and pharmaceutical compositions of the invention are of particular relevance in the treatment of diseases associated with antibiotic-resistant microbes.Type: ApplicationFiled: December 3, 2015Publication date: December 28, 2017Inventors: Kamil Önder, Roelf Datema, Dale Mitchell, Ivan Kondratov
-
Publication number: 20170340613Abstract: The present invention relates to novel compounds of formula (I) suitable e.g. as therapeutic agents for use in the treatment of mammalian disease and in particular to novel therapeutic agents suitable for use in the treatment of microbial infection in mammals. The present invention further relates to the use of pharmaceutical compositions comprising said agents in the treatment of medical conditions in mammals, in particular in the treatment of microbial infection. The agents and pharmaceutical compositions of the invention are of particular relevance in the treatment of diseases associated with antibiotic-resistant microbes. The present invention also relates to processes for making said agents.Type: ApplicationFiled: December 3, 2015Publication date: November 30, 2017Inventors: Kamil Önder, Roelf Datema, Dale Mitchell, Ivan Kondratov
-
Publication number: 20170334887Abstract: The present invention relates to novel therapeutic agents suitable for use in the treatment of mammalian disease and in particular to novel therapeutic agents suitable for use in the treatment of microbial infection in mammals. The present invention further relates to the use of pharmaceutical compositions comprising said agents in the treatment of medical conditions in mammals, in particular in the treatment of microbial infection. The agents and pharmaceutical compositions of the invention are of particular relevance in the treatment of diseases associated with antibiotic-resistant microbes.Type: ApplicationFiled: December 3, 2015Publication date: November 23, 2017Inventors: Kamil Önder, Roelf Datema
-
Patent number: 5656617Abstract: Antivirally active compounds of formula (I), wherein R.sup.1 is hydrogen, hydroxy, mercapto or amino; R.sup.2 is hydrogen, hydroxy, fluoro, chloro or amino; R.sup.3 and R.sup.4 are independently selected from (II), (III), amino, hydroxy or an ether or ester residue thereof, or R.sup.3 together with R.sup.4 is (IV), wherein M is hydrogen or a pharmaceutically acceptable counterion; and n is 1 or 2; with the proviso that, when R.sup.2 is amino and R.sup.3 and R.sup.4 are hydroxy, R.sup.1 is not hydroxy and in addition, when n=1, R.sup.1 is not hydrogen, and pharmaceutically acceptable salts thereof; processes for preparation of said compounds, a pharmaceutical composition comprising said compounds, methods for treatments of virus infections as well as use of compounds of formula (I) without the proviso for the manufacture of a medicament for treatment of AIDS.Type: GrantFiled: June 7, 1995Date of Patent: August 12, 1997Assignee: Medivir ABInventors: Bjorn Gunnar Lindborg, Roelf Datema, Karl Nils Gunnar Johansson, Bo Fredrik Oberg
-
Patent number: 5565461Abstract: The present invention is directed to a method of treating an HIV infection in a host in need of such treatment which comprises administering an effective anti-HIV amount of a compound having the formula ##STR1## wherein: R.sup.1 is hydrogen, hydroxyl;R.sup.2 is amino;R.sup.3 and R.sup.4 are independently selected from hydroxyl or an ester residue of said hydroxyl group derived from R.sup.6 COOH, wherein R.sup.6 is hydrogen, or C.sub.1 -C.sub.3 alkyl; and n is 1; or a pharmaceutically acceptable salt thereof.Type: GrantFiled: April 3, 1995Date of Patent: October 15, 1996Assignee: Medivir ABInventors: Bj orn G. Lindborg, Roelf Datema, Karl N. G. Johansson, Bo F. Oberg
-
Patent number: 5409906Abstract: A compound of the formula ##STR1## wherein the radicals A, X, R.sup.1, R.sup.2 and R.sup.3 are defined as follows:A: ##STR2## X: (a) O (b) S(c) CH.sub.2R.sup.1 : H; alkyl containing 1-3 carbon atoms;--CH.dbd.CH.sub.2 ; --CH.dbd.CH--CH.sub.3 ; --CH.sub.2 --CH.dbd.CH.sub.2 ; ##STR3## --C.tbd.CH p1 R.sup.2 : H; or R.sup.2 constitutes together with R.sup.3 a carbon--carbon bondR.sup.3 : H; F; Cl; Br; I; N.sub.3 ; CN; C.tbd.CH; OH; OCH.sub.3 ; CH.sub.2 OH; and when R.sup.3 is F; Cl; Br; I; N.sub.3 ; CN; C.tbd.CH; OH; OCH.sub.3 or CH.sub.2 OH it may have either the cis-configuration or trans-configuration relative to the hydroxymetyl function at position 4', or R.sup.3 constitutes together with R.sup.2 a carbon--carbon bond, and therapeutically acceptable salts thereof, for use in therapy, in particular for the treatment of HIV virus infections.Type: GrantFiled: April 1, 1993Date of Patent: April 25, 1995Assignee: Medivir ABInventors: Roelf Datema, Zsuzanna M. I. Kovacs, Karl N. G. Johansson, Bjorn Lindborg, Goran B. Stening, Bo. F. Oberg
-
Patent number: 5284837Abstract: Antivirally active compounds of formula (I), wherein R.sup.1 is hydrogen, hydroxy, mercapto or amino; R.sup.2 is hydrogen, hydroxy, fluoro, chloro or amino; R.sup.3 and R.sup.4 are independently selected from (II), (III), amino, hydroxy or an ether or ester residue thereof, or R.sup.3 together with R.sup.4 is (IV), wherein M is hydrogen or a pharmaceutically acceptable counterion; and n is 1 or 2; with the proviso that, when R.sup.2 is amino and R.sup.3 and R.sup.4 are hydroxy R.sup.1 is not hydroxy and in addition, when n=1, R.sup.1 is not hydrogen, and pharmaceutically acceptable salts thereof; processes for preparation of said compounds, a pharmaceutical composition comprising said compounds, methods for treatments of virus infections as well as use of compounds of formula (I) without the proviso for the manufacture of a medicament for treatment of AIDS.Type: GrantFiled: December 26, 1990Date of Patent: February 8, 1994Assignee: Medivir ABInventors: Bjorn G. Lindborg, Roelf Datema, Karl N. G. Johansson, Bo F. berg
-
Patent number: 5215971Abstract: Use of a compound of the formula ##STR1## wherein A is .beta.-2'-deoxy-D-ribofuranosyl or .beta.-D-arabinofuranosyl;R.sup.1 is hydroxy or amino;R.sup.2 is cycloalkyl or alkyl-substituted cycloalkyl containing 1-5 carbon atoms; saturated or unsaturated, straight or branched alkyl containing 1-5 carbon atoms which may be unsubstituted or substituted with halogen, hydroxy, mercapto, trifluoroalkyl or difluoroalkyl containing 1-3 carbon atoms, phenoxy or alkoxy containing 1-3 carbon atoms; phenyl or phenylalkyl containing 1-3 carbon atoms in the alkyl part, or a physiologically acceptable salt thereof,for manufacture of a medicament for therapeutic or prophylactic control or treatment of retrovirus, especially HIV, or hepatitis B virus infections in animal and man and to a method of such treatment.Type: GrantFiled: July 2, 1991Date of Patent: June 1, 1993Assignee: Medivir ABInventors: Roelf Datema, Kristina B. Gotthammar, Karl N. G. Johansson, Zsuzsanna M. I. Kovacs, Bjorn G. Lindborg, Goran B. Stening, Bo F. berg
-
Patent number: 5215970Abstract: A compound of the formula ##STR1## wherein the radicals A, X, R.sup.1, R.sup.2 and R.sup.3 are defined as follows: ##STR2## R.sup.2 : H; or R.sup.2 constitutes together with R.sup.3 with a carbon - carbon bondR.sup.3 : H; F; Cl; Br; I; N.sub.3 ; CN; C.tbd.CH; OH; OCH.sub.3 ; CH.sub.2 OH; and when R.sup.3 is F; Cl; Br; I; N.sub.3 ; CN; C.tbd.CH; OH; OCH.sub.3 or CH.sub.2 OH it may have either the cis-configuration or trans-configuration relative to the hydroxymethyl function at position 4', or R.sup.3 constitutes together with R.sup.2 a carbon - carbon bond, and therapeutically acceptable salts thereof, for use in therapy, in particular for the treatment of HIV infections.Type: GrantFiled: November 20, 1991Date of Patent: June 1, 1993Assignee: Medivir ABInventors: Roelf Datema, Zsuzanna M. I. Kovacs, Karl N. G. Johansson, Bjorn G. Lindborg, Goran B. Stening, Bo F. Oberg